Multiple China Biotech VC, PE Deals Kick Off A Strong Start To 2024
Executive Summary
Jiangsu Vcare Pharmatech, Neurodawn Pharmaceutical and Shanghai Synvida Biotechnology stand out with funding rounds that each grossed roughly CNY200m ($28m) and above.